Business Context and Reporting Period
This Form 8-K Current Report from Biote Corp. (Nasdaq: BTMD) covers events occurring on January 29, 2025, with an effective date of February 1, 2025. The filing details a significant leadership transition involving the resignation of the Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation agreements.
- New CEO Base Salary: $700,000 annually.
- New CEO Bonus Eligibility: Up to 85% of base salary.
- New CEO Relocation Allowance: Up to $200,000.
- New CEO Equity Grant: Option to purchase 1,500,000 shares of Class A common stock.
- Outgoing CEO Severance: $621,700 cash payment.
- Outgoing CEO Consulting Fee: $20,000 per month (plus $600/hour for hours exceeding 33/month).
Material Changes
The primary material change is the departure of Teresa S. Weber as Chief Executive Officer and Board member. Her resignation was accepted by the Board and is effective February 1, 2025. The filing explicitly states the resignation did not result from any disagreement regarding the Company's operations, policies, or practices.
Concurrently, Bret Christensen was appointed as the new Chief Executive Officer and a member of the Board of Directors (Class III director) effective February 1, 2025.
Outlook, Risks, and Unusual Items
Management Commentary and Transition:
- Outgoing CEO Role: Ms. Weber will serve as a strategic advisor under a consulting agreement through February 1, 2026. Her equity awards will continue to vest through this date.
- Incoming CEO Background: Mr. Christensen brings extensive experience from DermTech, Inc., Insulet Corporation (where he oversaw sales growth from $367 million to $1.1 billion), Myriad Genetics, and Hologic, Inc.
- Compensation Structure: The new CEO's employment is at-will. The outgoing CEO's severance is contingent upon executing a general release of claims.
Risks and Contingencies:
- Change of Control: Under the consulting agreement, Ms. Weber's equity awards will vest and become exercisable in full if a change of control occurs prior to the termination of the agreement.
- Equity Timing: The grant of the Initial Option to Mr. Christensen is subject to the Company's trading window reopening, with a deadline of 30 days after the effective date.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise terms for the 1,500,000 share option granted to Bret Christensen in the upcoming Form 10-Q.
- Confirm the total cash outflow for Teresa Weber's severance ($621,700) and the duration of her consulting fees ($20,000/month) in the next quarterly report.
- Review the full text of the Transition Agreement and Consulting Agreement (to be filed as exhibits to the Q1 2025 Form 10-Q) for specific definitions of "Cause" and termination conditions.
- Monitor the Company's trading window status to confirm the timing of the equity grant to the new CEO.